HEMGENIX - AN OVERVIEW

Amount of suitable patients: CDEC mentioned the uncertainty in the quantity of sufferers with reasonably extreme to severe hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some people who are classified as acquiring delicate or reasonable sickness could have a significant bleed